The items were successfully added to the cart.
GLP-1 analogues have contributed significantly to the treatment of T2DM, as these therapies result in better glycemic control through a variety of mechanisms.
It is well known that glucagon acts on the liver to stimulate glycogenolysis and gluconeogenesis.
The liver is the primary site of insulin clearance from plasma and excessive accumulation of fat in the liver significantly impairs the process.
Levels of the proinflammatory adipokine leptin are increased in obesity, and this hormone has been called “an active player in the development of NAFLD”.
Patients with NAFLD or NASH have increased small dense LDL and an increased risk of cardiovascular disease.